PL265
PL265 is an orally active dual enkephalinase inhibitor. PL265 is a prodrug of PL254, which can simultaneously and efficiently inhibit neutral endopeptidase (Neprilysin) and Aminopeptidase N. PL265 can effectively protect and significantly increase the local concentration of enkephalins (such as Met-Enkephalin and Leu-Enkephalin) released by cells at the pain or inflammation sites, thereby activating μ and δ opioid receptors to produce a potent analgesic effect. PL254 can also inhibit leukotriene A4 hydrolase (LTA4H), which may contribute to its additional anti-inflammatory effect by reducing the production of pro-inflammatory mediator leukotriene B4 (LTB4) . PL265 can be used in non-addictive chronic pain research[1].
Product Specifications
CAS Number
1206514-50-2
UNSPSC
12352005
Target
Endogenous Metabolite; Leukotriene Receptor; Opioid Receptor
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
Field of Research
Inflammation/Immunology; Neurological Disease
Smiles
CC(C)C(OC(C)OC(N[C@@H](C)P(C[C@@H](CC1=CC=C(C2=CC=CC=C2)C=C1)C(N[C@@H](C)C(O)=O)=O)(O)=O)=O)=O
Molecular Formula
C28H37N2O9P
Molecular Weight
576.58
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human Neutrophil Peptide-1, NP-1; HNNP-1 ELISA KIT
Human Neutrophil Peptide-1, NP-1; HNNP-1 ELISA KIT
Human Neutrophil Peptide-1, NP-1; HNNP-1 ELISA KIT
Human Neutrophil Peptide-1, NP-1; HNNP-1 ELISA KIT
